Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas

Daniel F. Brown, M. Anas Dababo, Christa L. Hladik, Kathleen P. Eagan, Charles L. White, Elisabeth J. Rushing

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Several primary central nervous system (CNS) neoplasms, including meningiomas, spinal cord ependymomas, and acoustic nerve schwannomas, express hormone receptors. In the present study, we investigated hormone receptor immunoreactivity in hemangioblastomas on the basis of recent reports of these tumors complicating pregnancy. We also evaluated cases of renal cell carcinoma (RCC) metastatic to the CNS, hypothesizing that estrogen receptor (ER), progesterone receptor (PR), or androgen receptor (AR) immunoreactivity might help to distinguish between these histologically similar neoplasms. Immunohistochemical analysis for ERs, PRs, and ARs was performed on paraffin-embedded sections of 27 hemangioblastomas, 12 primary clear cell RCCs, and 5 clear cell RCCs metastatic to the CNS. All of the hemangioblastomas demonstrated PR immunoreactivity, whereas 10 of 12 primary RCCs were negative. In addition, four of the five metastatic RCC were PR positive. All but one primary RCC were ER negative. AR immunoreactivity was seen in three hemangioblastomas, five primary RCCs, and one metastatic RCC. Although hormone receptor immunoreactivity was unable to distinguish between hemangioblastoma and clear cell RCC metastatic to the CNS, the identification of PR immunoreactivity in hemangioblastomas is a new finding that might have adjuvant therapy treatment implications.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalModern Pathology
Issue number1
StatePublished - Jan 1998


  • Androgen receptor
  • Clear cell renal cell carcinoma
  • Estrogen receptor
  • Hemangioblastoma
  • Immunohistochemistry
  • Progesterone receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas'. Together they form a unique fingerprint.

Cite this